Nyxoah SA (NYXH): Financial results for Q3 2026
Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Conc
How this was made
The 30-second read
Why it matters
The earnings release provides fresh revenue numbers and guidance, offering traders a basis for short‑term positioning.
Market read
First‑time earnings disclosure with modest revenue growth and updated guidance could generate modest buying pressure.
Timing
today
Background
Nyxoah SA, a medical‑technology company listed on Nasdaq and Euronext Brussels, filed a Form 6‑K reporting its Q3 2026 earnings and full‑year guidance.
Ticker impact
NYXH reported Q3 2026 results with €9.2M net revenue and issued full‑year 2026 guidance of €33‑35M.
likely support as investors price in issued revenue outlook
First‑time earnings release with sequential revenue growth and issued full‑year guidance suggests improved market perception.
Market effects
Positive earnings may lift other med‑tech and sleep‑apnea device makers.
May boost European and US biotech sentiment.
Moderate, limited to healthcare sector.
Key entities
- companyNyxoah SA
Medical‑technology firm developing the Genio OSA device.
